Strong planning and evaluation has been critical for the development of the research infrastructure at the Hollings Cancer Center (HCC) and is carried out through multiple feed back mechanisms, both external and internal. The HCC External Scientific Advisory Board is the primary external mechanism for review and advice on the HCC's progress in research. Internal mechanisms include the advice and counsel of HCC's Senior Leaders who formally comprise the HCC Executive Council;the HCC Research Committee;an Internal Scientific Advisory Board that meets annually and is comprised of MUSC institutional leaders and officials;and a Clinical Research Oversight Committee. Other planning and evaluation efforts occur at the program and shared resource levels. In 2005, Dr. Kraft and the Senior Leadership developed a strategic road map to guide the HCC development over a five year period. This road map outlines nine strategic directions for research to be developed, the need for expanded services within existing shared research resources as well as new shared research resources, and organizational strategies to improve collaboration and interdisciplinary interactions. This road map is regularly re-visited, reviewed for progress and updated specifically with the input of new members of the Senior Leadership team as they have come on board.

Public Health Relevance

The ongoing and clearly defined formative and summative evaluation and planning processes of the Hollings Cancer Center has been key to its growth in research in terms of extramural funding, enrollment onto clinical trials and dissemination of research results in the medical literature.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA138313-05
Application #
8456103
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
5
Fiscal Year
2013
Total Cost
$73,722
Indirect Cost
$23,741
Name
Medical University of South Carolina
Department
Type
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Wrangle, John M; Velcheti, Vamsidhar; Patel, Manish R et al. (2018) ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol 19:694-704
Panneer Selvam, Shanmugam; Roth, Braden M; Nganga, Rose et al. (2018) Balance between senescence and apoptosis is regulated by telomere damage-induced association between p16 and caspase-3. J Biol Chem 293:9784-9800
Jin, Junfei; Lu, Zhongyang; Li, Yanchun et al. (2018) LPS and palmitate synergistically stimulate sphingosine kinase 1 and increase sphingosine 1 phosphate in RAW264.7 macrophages. J Leukoc Biol 104:843-853
Janakiraman, Harinarayanan; House, Reniqua P; Gangaraju, Vamsi K et al. (2018) The Long (lncRNA) and Short (miRNA) of It: TGF?-Mediated Control of RNA-Binding Proteins and Noncoding RNAs. Mol Cancer Res 16:567-579
Rojewski, Alana M; Tanner, Nichole T; Dai, Lin et al. (2018) Tobacco Dependence Predicts Higher Lung Cancer and Mortality Rates and Lower Rates of Smoking Cessation in the National Lung Screening Trial. Chest 154:110-118
Joseph, Anne M; Rothman, Alexander J; Almirall, Daniel et al. (2018) Lung Cancer Screening and Smoking Cessation Clinical Trials. SCALE (Smoking Cessation within the Context of Lung Cancer Screening) Collaboration. Am J Respir Crit Care Med 197:172-182
Kim, Myung Jong; Jeon, Sohee; Burbulla, Lena F et al. (2018) Acid ceramidase inhibition ameliorates ?-synuclein accumulation upon loss of GBA1 function. Hum Mol Genet 27:1972-1988
Ramshesh, Venkat K; Lemasters, John J (2018) Imaging of Mitochondrial pH Using SNARF-1. Methods Mol Biol 1782:351-356
Jiang, Yu Lin; Zhu, Yun; Moore, Alfred B et al. (2018) Biotinylated Bioluminescent Probe for Long Lasting Targeted in Vivo Imaging of Xenografted Brain Tumors in Mice. ACS Chem Neurosci 9:100-106
Chatterjee, Shilpak; Chakraborty, Paramita; Daenthanasanmak, Anusara et al. (2018) Targeting PIM Kinase with PD1 inhibition Improves Immunotherapeutic Antitumor T-cell Response. Clin Cancer Res :

Showing the most recent 10 out of 536 publications